Clinical Trial Update: Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Lanreotide Autogel and Sandostatin LAR Depot for symptoms of malignant carcinoid syndrome; study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Carcinoid Syndrome

Drugs mentioned

• Lanreotide Autogel (lanreotide)
• SANDOSTATIN LAR DEPOT (OCTREOTIDE ACETATE)

Snippet

Sponsor: Ipsen | Conditions: Malignant Carcinoid Syndrome | Phase 3 | Status: TERMINATED